UBS analyst Alex Kramm lowered the firm’s price target on CME Group to $220 from $226 and keeps a Buy rating on the shares after the company provided its December metrics update. Average daily volume finished below his expectations largely due to weakness in Interest Rates and Equities, and this was only partially offset by stronger-than-expected pricing, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CME:
- CME Group upgraded to Outperform from Neutral at Credit Suisse
- CME Group says ADV increased 7% in December to 19.2M contracts
- CME Group price target lowered to $250 from $270 at Piper Sandler
- CME Group’s Micro WTI options volume surpasses 100K contracts traded
- CME Group Declares Annual Variable Dividend